Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.47 |
| ▸ | WNT3A | P56704 | 2/20 | 0.46 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.44 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31614765 | 1.00 | USP30 (0.48) | USP30PDE4BWNT3APROKR1SLC34A1 | |
| SCHEMBL20281618 | 0.90 | PDE4B (0.59) | USP30PDE4BWNT3APROKR1KDM4E | |
| SCHEMBL20281685 | 0.89 | PROKR1 (0.56) | USP30PDE4BWNT3APROKR1KDM4E | |
| SCHEMBL31227594 | 0.87 | WNT3A (0.58) | PDE4BWNT3AKDM4EGPR119 | |
| SCHEMBL31655309 | 0.87 | PDE4B (0.47) | USP30PDE4BKDM4EGPR119 | |
| SCHEMBL25888795 | 0.87 | PDE4B (0.47) | USP30PDE4BKDM4EGPR119 | |
| SCHEMBL23090083 | 0.86 | PDE4B (0.46) | USP30PDE4BSLC34A1KDM4EGPR119 | |
| SCHEMBL20757641 | 0.86 | PDE4B (0.46) | USP30PDE4BPROKR1KDM4EGPR119 | |
| SCHEMBL30094557 | 0.86 | PDE4B (0.46) | USP30PDE4BPROKR1KDM4EGPR119 | |
| SCHEMBL31405376 | 0.86 | PDE4B (0.46) | USP30PDE4BSLC34A1KDM4EGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109790112-B | Cyanopyrrolidine derivatives having activity as USP30 inhibitors | 特殊治疗有限公司 | 2022-08-26 | — | — | CN | disclosed |
| US-11014912-B2 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-05-25 | — | — | US | disclosed |
| US-11014912-B2 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-05-25 | — | — | US | disclosed |
| EP-3519385-B1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2020-11-18 | — | — | EP | disclosed |
| EP-3519385-B1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2020-11-18 | — | — | EP | disclosed |
| EP-3519385-A1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | Mission Therapeutics Limited (GB) | 2019-08-07 | — | — | EP | disclosed |
| WO-2018060689-A1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2018-04-05 | — | — | WO | disclosed |
| WO-2018060689-A1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11014912-B2 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | USP30, USP39, USP28 | USP30 1/4885PDE4B 2531/4885WNT3A 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.